Invitrogen™ Tocilizumab Recombinant Human Monoclonal Antibody (rhPM-1 (Tocilizumab))

Human Recombinant Monoclonal Antibody

Supplier:  Invitrogen™ MA548061

Catalog No. PIMA548061

Description

Specificity: Tocilizumab binds specifically to both the membrane bound and soluble forms of human IL-6R. The IL6 receptor is a protein complex consisting of an IL-6 receptor subunit (IL6R) and interleukin 6 signal transducer Glycoprotein 130. Interleukin 6 (IL6) is a potent pleiotropic cytokine that regulates cell growth and differentiation and plays an important role in immune response.

Tocilizumab (Actemra) is a humanized monoclonal antibody that is developed by Hoffmann-La Roche and Chugai for the treatment of patients with rheumatoid arthritis (RA) and systemic juvenile idiopathic arthritis, a severe form of arthritis in children. Tocilizumab binds to the interleukin-6 receptor (IL-6R) and blocks its interaction with interleukin 6 (IL-6), hindering IL-6 from exerting its pro-inflammatory effects.

Specifications

• Antigen: Tocilizumab
• Classification: Recombinant Monoclonal
• Concentration: 1 mg/mL
• Formulation: PBS with 0.02% ProClin 300
• Host Species: Human
• Purification Method: Protein A
• Regulatory Status: RUO
• Target Species: Human
• Product Type: Antibody
• Isotype: IgG1 κ

• Applications: ELISA, Inhibition Assays
• Clone: rhPM-1 (Tocilizumab)
• Conjugate: Unconjugated
• Gene Alias: Actemra; Atlizumab; MRA; R-1569; RHPM-1; RO-4877533
• Immunogen: The original antibody was generated by CDR grafting of mouse PM-1 antibody onto human REI and NEW framework regions to create rhPM-1.
• Quantity: 200 μg
• Primary or Secondary: Primary
• Content And Storage: Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
• Form: Liquid